Thromb J. 2011 Jan 27;9(1):3. doi: 10.1186/1477-9560-9-3.

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement.

Thrombosis journal

George Dranitsaris, Valentina Jelincic, Yoonhee Choe

PMID: 21272316 PMCID: PMC3039553 DOI: 10.1186/1477-9560-9-3

Abstract

BACKGROUND: Patients undergoing elective total hip replacement (THR) surgery are at an increased risk for venous thromboembolic events (VTEs). Dalteparin and enoxaparin are recommended as thromboprophylaxis for at least 10 days in these patients. Even though both agents have proven clinical effectiveness through placebo controlled studies, there have been no head to head trials to assess comparative effectiveness. Indirect statistical techniques were used to compare safety and efficacy between dalteparin and enoxaparin following THR surgery.

METHODS: A literature search was conducted from January 1980 to November 2009 for randomized trials evaluating dalteparin or enoxaparin prophylaxis in THR patients. In trials where a common control was used (e.g. placebo), indirect statistical comparisons between dalteparin and enoxaparin were performed using meta regression analysis with active drug as the primary independent variable.

RESULTS: A total of nine placebo controlled enoxaparin (n = 5) and dalteparin (n = 4) trials met the inclusion criteria. THR patients treated with enoxaparin or dalteparin had a 50% VTE risk reduction compared to the placebo control (RR = 0.50, p < 0.001). This benefit was achieved without a significant increase in the risk for major bleeds (RR = 1.19, p = 0.76), heparin induced thrombocytopenia (HIT) (RR = 1.13, p = 0.83) or death (RR = 0.72, p = 0.59). The indirect comparison was not able to find significant differences between enoxaparin and dalteparin in terms of VTEs (p = 0.36), major bleeds (p = 0.45), HIT (p = 0.48) and death (p = 0.86).

CONCLUSIONS: The findings suggested comparable safety and efficacy between dalteparin and enoxaparin in TKR patients. Therefore, treatment decisions should be based on other considerations, such as patient or physician preference, ease of administration and cost.

References

1. J Bone Joint Surg Am. 1994 Jan;76(1):3-14 - PubMed
2. Thromb Haemost. 1988 Dec 22;60(3):407-10 - PubMed
3. Biometrics. 1994 Dec;50(4):1088-101 - PubMed
4. Lancet. 1996 Jul 27;348(9022):224-8 - PubMed
5. Haemostasis. 1989;19(1):5-12 - PubMed
6. Arch Orthop Trauma Surg. 2006 Jan;126(1):1-5 - PubMed
7. N Engl J Med. 1986 Oct 9;315(15):925-9 - PubMed
8. N Engl J Med. 1996 Sep 5;335(10):696-700 - PubMed
9. Thromb Haemost. 1997 Jan;77(1):26-31 - PubMed
10. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
11. J Bone Joint Surg Am. 2001 Mar;83(3):336-45 - PubMed
12. Arch Intern Med. 2000 Jul 24;160(14):2199-207 - PubMed
13. N Engl J Med. 1994 Dec 15;331(24):1630-41 - PubMed
14. Ann Chir Gynaecol. 1995;84(1):85-90 - PubMed
15. J Bone Joint Surg Br. 1991 May;73(3):434-8 - PubMed
16. J Thromb Haemost. 2005 Mar;3(3):473-81 - PubMed
17. BMJ. 2003 Mar 1;326(7387):472 - PubMed
18. BMC Cancer. 2009 Jan 27;9:34 - PubMed
19. J Clin Epidemiol. 1997 Jun;50(6):683-91 - PubMed
20. J Orthop Sci. 2008 Sep;13(5):442-51 - PubMed
21. Thromb Res. 1998 Mar 15;89(6):281-7 - PubMed
22. Ann Pharmacother. 2002 Jun;36(6):1042-57 - PubMed
23. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
24. J Arthroplasty. 1998 Feb;13(2):180-5 - PubMed
25. J Manag Care Pharm. 2007 Jul-Aug;13(6):475-86 - PubMed
26. Chest. 2008 Jun;133(6 Suppl):381S-453S - PubMed
27. Ann Intern Med. 1991 Apr 1;114(7):545-51 - PubMed
28. Appl Health Econ Health Policy. 2009;7(1):43-59 - PubMed
29. Arch Intern Med. 2000 Jul 24;160(14):2208-15 - PubMed
30. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed

Publication Types

• Journal Article